| Code | CSB-RA013481MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to PRX-005, targeting microtubule-associated protein tau (MAPT). MAPT plays a critical role in stabilizing neuronal microtubules and maintaining axonal transport in the central nervous system. Under pathological conditions, MAPT becomes hyperphosphorylated and forms neurofibrillary tangles, a hallmark of several neurodegenerative disorders collectively termed tauopathies. These include Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, and chronic traumatic encephalopathy. Aberrant tau aggregation disrupts normal cellular function and contributes to neuronal death and cognitive decline.
PRX-005 is a humanized monoclonal antibody designed to target pathological forms of tau protein, particularly focusing on mid-region epitopes. This reference antibody has been investigated in preclinical and clinical studies for its potential to reduce tau pathology and slow disease progression in tauopathies. As a research-grade biosimilar, this antibody provides investigators with a valuable tool for studying tau biology, evaluating tau-directed therapeutic mechanisms, exploring biomarker development, and investigating neurodegenerative disease pathways in various experimental models.
There are currently no reviews for this product.